Active TN Research Projects Funded by FPRF

InstitutionMoleculeType of ProductDiscoveryDevelopomentPreclinicalPhase 1Phase 2Phase 3Status
Danish Headache CenterBotulinum ToxinMeasure efficacy of Botulinum in TN patients and Biomarker identificationXParticpant recruitment has been a challenge, so the research has been extended 18 months so enough participants enroll to draw statistical conclusions.
NeuronaStem cellInhibitory stem cellsXWorking well in epilepsy clinical. Revised cells ready to test in TN animal models
UCSF9087
other A2a receptors		Novel compound targeting A2A adrenergic receptorXDrug 9807 worked successfully enough to submit for patent protection.. Testing on related drug candidates will be available by mid-Q2 2026
UCSFBlu 782ACVR1 inhibitorXBLU782 is in human clinical trials for a different disease. Testing efficacy in animal TN models
Univ. of NevadaPeptidePeptide Fragment stimulates lipid systemXWork moving more towards IND enabling studies for TN that will be needed to begin clinical work. The current Alzheimer's phase 2 clinical trial continues to perform well.
University of FloridaC 194 and analog NGO-0857391Regulation of the number and strength of NaV 1.7 pain signals by suppression of the CRMP2 proteinXAdministration of C194 showed significant reduction of mechanical and cold hypersensitivity in female mice. Testing now in male mice. Funding and expertise secured to move the lead compound towards clinical trials ASAP.
Vanderbilt UniversityRepurposed drug combinationNew formulation of 2 FDA approved drugs for use as a patient administered rescue treatmentXFPRF connected the Vanderbilt researchers with a drug manufacturing resource in January 2026. Once the combination drug can be manufactured, a clinical trial can be started.
OHSUTMD/TN diagnosisDiagnostic tool to help diagnose TMD from TN more accuratelyXThe TN diagnositc tool has ben shown to produce 90% TN classic diagnosis. Funding has been secured to allow validaiton by other investigators to test broad applicability.
Univ. New MexicoHC2-LC3Single chain Fragment variable antibodyXHigh Bioscience is raising funds to test this therapy in a clinical trial involving male veterans since the mouse work showed it helped male mice but not female mice. We believe this should help female humans, and would begin to test in humans females if success in male participants.
UCSFTranscranial Magnetic Stimulation (TMS)HFrTMSXProject going well demonstrating significant benefits when procedure is administered correctly. Final tests being completed and manuscript for publication is being written.
Joint development of FPRF and Allos TherapeuticsR BaclofenR baclofen is the active part of the drug baclofen. Animal and Human testing has shown that R baclofen provides five times the pain reduction, and fewer side effects than the normal baclofenXPreparing clinical trial proposal for a Ph2 study in TN patients
NavegaNT-Z001An epigenetic repressor of SCN9A delivered via AAV9XNavega received $9.85M CIRM grant to fund the pre-IND work necessary for them to start their phase I clinical trial. FPRF is making a further grant to support this work under a SAFE agreement.